

Supplementary Table 1. DMARDs used during the study period

Variable	Conventional DMARD group (n = 406)	Biologic DMARD group (n = 396)
Conventional DMARDs	406 (100.0)	386 (97.5)
Methotrexate	327 (80.5)	362 (91.4)
Hydroxychloroquine	226 (55.7)	62 (15.7)
Leflunomide	174 (42.9)	47 (11.9)
Sulfasalazine	72 (17.7)	28 (7.1)
Tacrolimus	55 (13.6)	18 (4.6)
Bucillamine	23 (5.7)	6 (1.5)
Mizoribine	8 (2.0)	5 (1.3)
Cyclosporine	3 (0.7)	2 (0.5)
Azathioprine	2 (0.5)	-
Biologic DMARDs	-	396 (100.0)
Adalimumab	-	212 (53.6)
Etanercept	-	130 (32.8)
Infliximab	-	58 (14.7)
Rituximab	-	33 (8.3)
Abatacept	-	23 (5.8)
Tocilizumab	-	7 (1.8)
Golimumab	-	2 (0.5)
Secukinumab	-	1 (0.3)

Values are presented as number (%). The number of agents used by each patient during the study period was counted. DMARD, disease-modifying antirheumatic drug.